Zymeworks Inc. filed a Form 8-K on August 25, 2026, disclosing that partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii)-containing regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, triggering a $250 million milestone payment to Zymeworks.

Key Highlights

  • FDA approval granted: Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii)-containing regimens for first-line HER2-positive gastroesophageal adenocarcinoma (GEA) treatment.
  • $250 million milestone earned: Zymeworks has earned a milestone payment of $250 million pursuant to the License and Collaboration Agreement with Jazz, based on the FDA approval in GEA.
  • Up to $1.3 billion in additional milestones: Zymeworks remains eligible to receive up to $1.3 billion in additional regulatory and commercial milestones.
  • Tiered royalties of 10% to 20%: Zymeworks is also eligible for tiered royalties of 10% to 20% on Jazz's net sales of zanidatamab in Jazz's licensed territories.
  • Two approved regimens: The approvals cover Ziihera plus Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+).
  • Exclusive licensing arrangement: Jazz holds exclusive rights to develop and commercialize zanidatamab worldwide, excluding certain territories covered by Zymeworks' agreement with BeOne Medicines Ltd., according to the filing.

Zymeworks Receives $250M Payment as FDA Clears Zanidatamab Regimens for GEA

According to the Form 8-K filed with the U.S. Securities and Exchange Commission on August 25, 2026, Zymeworks Inc. (NASDAQ:ZYME) disclosed that its partner Jazz Pharmaceuticals received FDA approval for two regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The filing states the approved regimens are Ziihera plus Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ IHC 3+ and IHC 2+/ISH+, and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ IHC 3+.

The filing reports that Zymeworks BC Inc., a subsidiary of the company, is party to an Amended and Restated License and Collaboration Agreement with Jazz Pharmaceuticals Ireland Limited, a subsidiary of Jazz Pharmaceuticals plc. Under this agreement, Jazz holds exclusive worldwide rights to develop and commercialize zanidatamab, excluding territories already covered by Zymeworks' agreement with BeOne Medicines Ltd. Pursuant to that agreement, the filing states that Zymeworks has earned a milestone payment of $250 million based on the FDA approval in GEA.

The filing further discloses that Zymeworks remains eligible to receive up to $1.3 billion in additional regulatory and commercial milestones, as well as tiered royalties of 10% to 20% on Jazz's net sales of zanidatamab in Jazz's licensed territories. The disclosure was made under Items 7.01 and 8.01 and was furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as the company noted in the filing. The report was signed by Kenneth Galbraith, Chair, President and Chief Executive Officer of Zymeworks Inc.

What Was Disclosed

Zymeworks disclosed via an 8-K dated August 25, 2026, that FDA approval of two zanidatamab-containing regimens for HER2-positive GEA triggered a $250 million milestone payment from partner Jazz Pharmaceuticals, with up to $1.3 billion in further milestones and tiered royalties remaining available.